Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab recommended over no tx
WEDNESDAY, March 4, 2020 (HealthDay News) — In a new clinical guideline from the American Gastroenterological Association, recently published in Gastroenterology, treatment recommendations are presented for patients with moderate-to-severe ulcerative colitis (UC).
Joseph D. Feuerstein, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues developed guidelines for medical management of adult outpatients with moderate-to-severe UC.
The authors recommend using infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ustekinumab over no treatment in adult outpatients with moderate-to-severe UC for induction and maintenance of remission. Infliximab or vedolizumab are recommended over adalimumab for induction of remission in adult outpatients with moderate-to-severe UC who are naive to biologic agents; tofacitinib should only be used in the setting of a clinical or registry study. Ustekinumab or tofacitinib are suggested rather than vedolizumab or adalimumab for induction of remission in adult outpatients with moderate-to-severe UC who have previously been exposed to infliximab, particularly those with primary nonresponse. Thiopurine monotherapy is not recommended for induction of remission in adult outpatients with active moderate-to-severe UC. For maintenance of remission, thiopurine monotherapy is recommended over no treatment for adult outpatients with moderate-to-severe UC in remission.
“This guideline takes a comprehensive and evidence-based look at available therapies to provide the most trusted guidance to-date on treatment options to ultimately improve the care of patients with moderate-to-severe UC,” Feuerstein said in a statement.
One author disclosed financial ties to the pharmaceutical industry.
Copyright © 2020 HealthDay. All rights reserved.